Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The researchers reported that compounds 11 to 13 derived from Westphalen-type steroids showed strong antiandrogenic activity in vivo, though their effects could not be attributed to 5α-reductase inhibition or androgen receptor binding.

This article reviews the potential of combining antiandrogenic and antiestrogenic treatments for BPH, highlighting aromatase inhibitors, but presents no new clinical results; further research is needed.

In this study, both honey and bee pollen may alleviate menopausal symptoms in breast cancer patients on antihormonal treatment, with no significant difference between the two.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

Hormonal contraceptives and therapies regulate organ functions and treat various conditions.

This research outlines that antiandrogens have mechanisms involving competitive inhibition of androgen binding and enzyme inhibition, with contraindications during pregnancy due to potential fetal risks.

This article discusses the complexities of androgen and antiandrogen therapies in women, detailing diagnostic measures, the effects on libido, and the potential benefits of new progestins with antiandrogenic properties, but presents no new empirical findings.

This review discusses the biology of antiandrogens and highlights available bioassay models to predict their therapeutic effects on human skin, reporting no new clinical results.

This study found that four new progesterone derivatives reduced prostate weight in gonadectomized hamsters, suggesting potent in vivo antiandrogenic effects similar to finasteride.

This abstract reviews the use and effects of various antiandrogens, finding clinical benefits in treating hyperandrogenism in women and improvements in urinary symptoms or cancer management in men, but it reports no new clinical results.

This review examines the effects of antiandrogens on female reproductive systems, particularly regarding environmental endocrine disruptors, and presents no new research findings.

This review summarizes the structural and chemical characteristics of current and novel antiandrogenic drugs but reports no new clinical findings.

This review discusses androgen manipulation strategies for conditions like benign prostatic hyperplasia and prostatic carcinoma but reports no new clinical results.

This article discusses drugs with anti-androgenic effects and their mechanisms but reports no new research findings.

This study suggests that antiandrogens may slightly reduce hirsutism severity compared to placebo, but evidence is weak and their relative efficacy remains uncertain.

This article describes the unusual anti-angiogenic effects of combined hormonal blockade but reports no new research findings.

This study reported that estrogen-progestin oral contraceptives, antiandrogens, and insulin sensitizers are more effective than placebo in treating hirsutism in women, with combination therapies generally proving superior to monotherapy.

This study found that newly synthesized steroidal trienones demonstrated stronger 5α-reductase inhibitory activity compared to dienones in various biological models, suggesting potential for developing enhanced antiandrogenic drugs.

This review discusses various anti-androgen treatments for hirsutism, including androgen receptor blockers and inhibitors, and emphasizes the role of diagnosis in selecting the most appropriate therapy, but reports no new clinical results.

This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

Antiandrogens can treat excess body hair and hair loss by blocking male hormones.

This review discusses various sex hormones and related compounds, including estrogens and anabolic steroids, but reports no new findings; it highlights existing literature from 2014 regarding their use and effects.

In this study of a postmenopausal woman with hyperandrogenism, GnRH agonist treatment significantly reduced testosterone levels, suggesting the androgen excess was ovarian in origin and indicating the potential of using GnRH agonists as a conservative treatment option when surgery is not feasible.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

This article discusses the mechanisms and therapeutic use of antiandrogens, specifically cyproterone acetate and chlormadinone acetate, in gynecological treatments without reporting new clinical results.

This meta-analysis found that combination oral contraceptive pills effectively treat hirsutism but recommends adding an antiandrogen if response is inadequate after six months.

This review discusses hormone replacement therapy for menopausal women, emphasizing DHEA's unique ability to convert into sex steroids only in targeted tissues, and reports no new clinical results.